INTRODUCTION
This update reviews the literature in the prevention and management of HIV infection as pertinent to the general internist. Our objectives were (1) to review the most recent data regarding HIV prevention, counseling, testing, and treatment, with a special focus on cost-effectiveness; (2) to discuss new findings regarding survival and general management of HIV, including a brief review of updated treatment guidelines and new antiretroviral medications; and (3) to discuss the intersection of HIV with other chronic diseases commonly encountered by generalist physicians. We included papers with both domestic and international relevance.
We performed a literature search of peer-reviewed studies published since July 2006. Initially, we performed a PUBMED search using the Medical Subject Heading (MeSH) term "HIV," limiting our search to English articles dealing with human subjects published in core clinical journals on or after July 1, 2006 . We narrowed our results to studies focusing on the following categories: prevention, counseling and testing, survival, management, and HIV and other chronic diseases. Additionally, we reviewed studies published since July 2006 in the major internal medicine journals and HIV specialty journals, and included articles based on recommendations by experts in the field. Final selection of articles was by group consensus of HIV experts and practicing HIV clinicians.
PREVENTION: THE ROLE OF MALE CIRCUMCISION
Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007;369:657-666.
More than 40 epidemiologic studies have suggested a beneficial effect of male circumcision in preventing HIV acquisition among heterosexual men. 1 The biological explanation for this may be limiting the vulnerable mucosal surface. Several recent randomized controlled trials were performed to assess safety and efficacy of male circumcision in reducing female-to-male HIV transmission. 2, 3 Gray et al. reported on the largest of these trials, performed in Rakai, Uganda. This study enrolled 4,996 uncircumcised, HIV-negative men aged 15-49 years who were randomly assigned to receive immediate circumcision or circumcision delayed for 24 months. The primary outcome was HIV incidence. This trial was stopped early after interim analysis showed significant efficacy for circumcision. In a modified intention to treat analysis, 24-month incidence was 0.66/100 person-years in the immediate circumcision group versus 1.33/100 personyears in the control group, corresponding to a 51% efficacy (95% CI, 16%-72%; P=0.006). Accounting for crossovers in an as-treated analysis, efficacy increased to 55% (95% CI, 22%-75%; P=0.003). HIV incidence was lower in the immediate circumcision group in all sociodemographic, behavioral, and sexually transmitted disease subgroups. This effect appeared to be stronger among men with two or more partners, extramarital partners, and during later follow-up periods. Moderate or severe adverse events were relatively rare. All adverse events resolved with treatment. Behaviors were similar in both groups. The Rakai study findings are consistent with the other two circumcision trials performed in Africa. 2, 3 One caveat is that circumcision in these studies was performed by trained personnel using sterile technique in well-equipped facilities. Complications might increase under less controlled conditions. Additionally, preliminary data from another study raise concern about potential increased HIV transmission to female partners of HIV-positive men circumcised as adults, although this difference was not statistically significant. 4 Still, the World Health Organization During the last 3 years, there has been renewed emphasis on expanding HIV testing in primary care. 6 Studies have previously demonstrated that under most conditions in the US, cost-effectiveness ratios for routine HIV testing are substantially less than the commonly used benchmark of $50,000 per quality-adjusted life year (QALY). 7, 8 More recent research taking into account new testing and treatment strategies and effects on future HIV transmission has strengthened these findings. Paltiel and colleagues used cost-effectiveness modeling to incorporate the effects of testing and treatment on future transmission. The number of infections that one person may transmit depends on the number of infective contacts, the behavioral risk of each contact, the efficiency of transmission, and the lifetime duration of HIV infectivity. In theory, HIV testing may decrease subsequent infections by decreasing risk behaviors and through viral suppression with antiretroviral therapy. However, testing and treatment might conversely increase subsequent infections by disinhibiting behavior and prolonging life, leading to more contacts.
They set the mean base lifetime transmission rate from a single infected individual (R 0 ) at 1.44. In their simulation model, they found that for a typical population (1% HIV prevalence) one-time screening had a cost-effectiveness ratio of $30,800 per QALY, and screening every 5 years a ratio of $32,300 per QALY. Assuming an adverse effect of HIV testing on future transmission (if testing were to increase transmission), one-time screening still conferred a net health benefit, with the cost-effectiveness ratio increased, but still a good value at $44,200/QALY. Screening every 3 to 5 years became quite costly, with cost-effectiveness ratios exceeding $100,000/QALY. However, using more favorable assumptions (that testing would reduce transmission) improved estimates of cost-effectiveness so that one-time routine HIV screening ratios remained below $50,000/QALY in settings where HIV prevalence was as low as 0.2%. One limitation is that the model incorporates effects on transmission directly from the screened individual to others, but not on more distant downstream transmission.
Sanders and colleagues focused on adults aged 55-75 years. In their Markov model incorporating prevalence, treatment, years and quality of life saved, transmission, and costs, they found that for older adults with a spouse or other sexual partner, one-time screening of populations with prevalence as low as 0.5% yielded favorable incremental cost-effectiveness in those 65 ($30,020/QALY) and those 75 years old ($41,520/QALY). Screening older adults without sexual partners was less cost-effective ($55,440/QALY for a 65 year old), but still approached the conventional threshold of $50,000/QALY.
Goldie and colleagues studied cost-effectiveness of HIV treatment in resource-limited settings. In Côte d'Ivoire, they compared treatment strategies not considered in developed settings, such as use of trimethoprim-sulfamethoxazole prophylaxis without antiretrovirals or prophylaxis plus antiretroviral therapy monitored with clinical criteria alone and not laboratory tests. Using conservative assumptions, they demonstrated that for all antiretroviral strategies, those combined with trimethoprim-sulfamethoxazole prophylaxis were in each case more effective (greater life expectancy) and more efficient (less incremental cost per year of life gained).
Prophylaxis alone was more efficient (incremental costeffectiveness ratio of $240/year gained) than antiretroviral therapy and prophylaxis without CD4 testing ($620/year gained) or antiretrovirals and prophylaxis with CD4 testing ($1,180/year gained). However, prophylaxis without antiretrovirals was also less effective in terms of increased undiscounted life expectancy (1.6 months) than strategies that included antiretroviral therapy, either without CD4 testing (10.7-45.9 months depending on criteria for initiation of therapy) or with CD4 testing (14 months). The authors used three times the local per capita GDP ($2,124) as a costeffectiveness threshold. Using this threshold, each strategy was economically attractive. The conclusions held up well to sensitivity analyses, with the exception of variation in the cost of antiretrovirals. Increases in antiretroviral costs had the greatest risk of driving costs per year of life saved significantly higher than the $2,124 GDP line. This study suggests that delivering HIV treatment can be economically reasonable in resource-limited settings. The study found that persons with HIV infection had a median survival beyond age 25 of 19.9 years, compared with 51.1 years in the general population. However, subgroup analysis found that in the late HAART era (2000-2005), survival beyond age 25 had increased to 32.5 years. Those patients who were hepatitis C negative and diagnosed in the late HAART era had the best survival at 38.9 years beyond age 25.
The strength of this study is the ability to capture accurate and comprehensive data for an entire population. There were no exclusion criteria, and all persons with HIV were included regardless of CD4 count, viral load, stage of disease, comorbidities, or treatment adherence. In addition, less than 3% of the cohort was lost to follow up. One potential limitation is that the measurement of survival from age 25 likely leads to lead time bias as most patients were diagnosed after age 40 and so presumably did not have disease at age 25. A second limitation is that the limited observation period may be too short to extrapolate long-term survival. Finally, because of Denmark's national health system, patients had excellent access to health care (>75% of patients were on HAART), and results may not be generalizable. Despite these limitations, this study predicts that a nearly 20-year increase in life expectancy is achievable with HAART.
MANAGEMENT When to Start
In December 2007 the US Department of Health and Human Services (DHHS) revised its guidelines for initiation of antiretroviral therapy. The recommendation is to initiate treatment in patients with a history of an AIDS-defining illness or with CD4 lymphocyte count <350 cells/mm 3 . This is a change from prior recommendations, which stated that asymptomatic persons with CD4 count between 200-350 cells/mm 3 should be offered treatment, but did not explicitly recommend treatment in this group. 9 The DHHS also recommends antiretroviral therapy regardless of CD4 lymphocyte count among (1) pregnant patients, (2) Abacavir hypersensitivity is an immunologically based, potentially life-threatening condition, requiring a high degree of clinical suspicion. 22 It is estimated to affect 5-8% of patients during the first 6 weeks of therapy. Symptoms of abacavir hypersensitivity are nonspecific and often similar to other drug side effects, which may lead to false-positive diagnoses. Previous studies have shown an association of MHC class I allele HLA-B*5701 and hypersensitivity. 23, 24 This study tested the hypothesis that prospective HLA-B*5701 testing and excluding those found to be positive would reduce the incidence of abacavir hypersensitivity. This prospective, multicenter, randomized, double-blind study was performed at 265 centers in 19 countries. The study had two arms: (1) those receiving prospective screening, and if found to be HLA-B*5701 positive, excluded from abacavir-containing treatment and (2) a control group, receiving abacavir under usual care, with HLA test results reviewed after the study. Epicutaneous patch testing was used as a "gold standard" for hypersensitivity.
A total of 1,956 subjects was evaluated: 980 prospective screening and 847 control subjects. Fifty-five were excluded from the prospective screening group after testing positive for HLA-B*5701. Results showed that 109 patients out of 1,956 (5.6%) were HLA-B*5701 positive. The incidences of both clinical (0.40; 95% CI, 0.25-0.62) and immunologically confirmed (OR 0.03; 95% CI,0.00-0.18) hypersensitivity reactions were lower in the prospective screening group. In multivariate analysis, only prospective screening was a significant negative predictor of hypersensitivity reaction. There were no immunologically diagnosed hypersensitivity reactions in the screened group. Current use of a protease inhibitor (PI) or introduction of a new NNRTI were predictors of clinically diagnosed hypersensitivity, not immunologically confirmed, suggesting that the symptoms were due to another drug, and not true abacavir hypersensitivity. The positive predictive value (PPV) of HLA-B*5701 for immunologically confirmed hypersensitivity was 47.9%, with a negative predictive value (NPV) of 100%. For clinically diagnosed hypersensitivity, the PPV was 61.2% and the NPV was 95.5%. Nineteen of 49 carriers (38.8%) in the control group tolerated abacavir, suggesting that HLA B*5701 is necessary, but not sufficient for hypersensitivity.
There are a few caveats. Although it performed well in this study, the patch test is for experimental proposes only. The population studied was largely Caucasian; however, other studies suggest HLA-B*5701 testing performs well in diverse populations. 25 Cost-effectiveness may vary across different settings. Prospective HLA-B*5701 testing can reduce the risk of abacavir hypersensitivity reactions and is now recommended by the DHHS for all patients before beginning an abacavir-containing regimen. This study population consisted of 23,437 HIV-infected patients. The authors calculated incidence rates of MI and determined the associations between MI and both PI and NNRTI exposure. Three hundred and forty-five patients had an MI during 94,469 person-years of observation. The incidence of MI increased from 1.53/1,000 person years in non-PIexposed individuals to 6.01/1,000 person-years in individuals A limitation of this study is its observational nature; unmeasured confounders might contribute to the findings. Additionally, there is the possibility of "channeling bias" whereby patients considered to be at higher risk might be placed on regimens considered safer from a cardiac standpoint. Adjusting for cardiac risk factors ameliorates but cannot completely account for this. Still, the results of this study confirm a relationship between duration of combination antiretroviral use and cardiovascular disease, and suggest that PI use is associated with MI, which may be in part attributable to lipid effects. There were 517 patients with MI, corresponding to an event rate of 3.3 per 1,000 person-years (95% CI: 3.0-3.6). Exposure to abacavir or didanosine in the past 6 months, but not cumulative exposure, was associated with an increased risk of MI compared to those with no recent use of those medications. The relative rate of MI for recent abacavir use was 1.90 (95% CI: 1.47-2.45), and the relative rate of MI for recent didanosine use was 1.49 (1.14-1.95). There was no increased risk of MI among patients who had been previously on didanosine or abacavir and been off these medications for more than 6 months compared to those who had never received them. After adjustment for predicted 10 year risk of coronary disease, 28 recent use of abacavir and didanosine was still associated with increased rates of MI (1.89, 95% CI 1.47-2.45 for abacavir and 1.49, 95% CI 1.14-1.95 for didanosine).
No association was observed between MI and cumulative exposure to zidovudine, stavudine, or lamivudine. There are some limitations. The possibility exists that persons with higher cardiovascular risk due to other factors might have been more likely to receive abacavir or didanosine. However, after adjustment for risk factors, including predicted 10-year coronary risk, increased rates of MI persisted for abacavir and didanosine. Additionally, the risk decreased after the drugs were discontinued, suggesting the increased risk is attributable to the drugs. Data for two other commonly prescribed NRTIs, emtricitabine and tenofovir, were not presented in this analysis due to lack of sufficient follow-up time.
The findings of this study merit additional investigation, which is underway. At this time, the DHHS has not changed their recommendations on the use of antiviral agents. 29 Clinicians should take into consideration individual patient characteristics and consider all available treatment options when deciding on the appropriate antiretroviral regimen for their patients. Institute. They determined standardized rate ratios (SRRs) for each and found the incidence for the following non-AIDSdefining cancers to be significantly higher in the HIV-infected population: anal (SRR 42.9; 95% CI, 34.1 to 53.3), vaginal (SRR 21.0; 95% CI, 11.2 to 35.9), Hodgkin lymphoma (SRR 14.7; 95% CI, 11.6 to 18.2), liver (SRR 7.7; 95% CI, 5.7 to 10.1), lung (3.3; 95% CI, 2.8 to 3.9), melanoma (SRR 2.6; 95% CI, 1.9 to 3.6), oropharyngeal (SRR 2.6; 95% CI, 1.9 to 3.4), leukemia (SRR 2.5; 95% CI, 1.6 to 3.8), colorectal (SRR 2.3; 95% CI, 1.8 to 2.9), and renal (SRR 1.8; 95% CI, 1.1 to 2.7). Among HIV-infected persons, incidence rates for melanoma, Hodgkin lymphoma, and colorectal, anal, and prostate cancer increased significantly over time, despite the introduction of HAART during the study period. However, anal cancer was the only type of cancer for which the relative incidence for HIVinfected persons compared with the general population increased over time.
Patel
In terms of risk factors, acquisition of HIV through malemale sex was associated with increased risk for Kaposi's sarcoma (KS) and non-Hodgkin lymphoma. Use of antiretroviral therapy was associated with decreased risk for KS, nonHodgkin lymphoma, and cervical, lung, breast, and colorectal cancer; low CD4 nadir was associated with increased risk of KS, non-Hodgkin lymphoma, cervical, anal, colorectal, and lung cancers. Hepatitis B or C coinfection was associated with increased risk of liver cancer.
Limitations include (1) no formal evaluation of cancer data in these cohorts, (2) inadequate tobacco data, and (3) the cohorts are not representative of the overall HIV-infected population in the US. Still, the study suggests that HIV-infected individuals are at an increased risk for certain cancers compared to the general population. Risks for some of these cancers may be reduced with currently available prevention strategies, and further work is needed to explore new strategies.
